{"entity":{"id":"nct05150691","kind":"trial","name":"A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Trastuzumab pamirtecan and Pertuzumab in advanced solid tumours, run by DualityBio Inc., now recruiting.","summary":"A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05150691 by DualityBio Inc., with 796 participants planned, started 2022-01-31 and due to reach its primary completion in 2027-08. Interventions recorded: DB-1303/BNT323, Pertuzumab Injection, Ritonavir and Itraconazole.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05150691","url":"https://clinicaltrials.gov/study/NCT05150691"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab-pamirtecan","pertuzumab"],"companies":["dualitybio","biontech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05150691","phase":"1/2","setting":"A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients With Advanced/Metastatic Solid Tumors","sponsor":"DualityBio Inc.","enrolled":796,"outcomes":[]},"route":"/trials/nct05150691/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/"},{"id":"trastuzumab-pamirtecan","kind":"drug","name":"Trastuzumab pamirtecan","route":"/drugs/trastuzumab-pamirtecan/"}],"company":[{"id":"biontech","kind":"company","name":"BioNTech","route":"/companies/biontech/"},{"id":"dualitybio","kind":"company","name":"Duality Biotherapeutics","route":"/companies/dualitybio/"}]}}